These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1487627)

  • 1. Paroxetine in the treatment of melancholia and severe depression.
    Tignol J; Stoker MJ; Dunbar GC
    Int Clin Psychopharmacol; 1992 Nov; 7(2):91-4. PubMed ID: 1487627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression.
    Baldwin DS; Hawley CJ; Abed RT; Maragakis BP; Cox J; Buckingham SA; Pover GH; Ascher A
    J Clin Psychiatry; 1996; 57 Suppl 2():46-52. PubMed ID: 8626363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression.
    Nemeroff CB
    J Clin Psychopharmacol; 1993 Dec; 13(6 Suppl 2):10S-17S. PubMed ID: 8106649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Paroxetine in the treatment of depression in geriatric patients--a double-blind comparative study with fluoxetine].
    Schöne W; Ludwig M
    Fortschr Neurol Psychiatr; 1994 Sep; 62 Suppl 1():16-8. PubMed ID: 7959520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of paroxetine compared with placebo in outpatients with major depression.
    Rickels K; Amsterdam J; Clary C; Fox I; Schweizer E; Weise C
    J Clin Psychiatry; 1992 Feb; 53 Suppl():30-2. PubMed ID: 1531820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients.
    Stuppaeck CH; Geretsegger C; Whitworth AB; Schubert H; Platz T; König P; Hinterhuber H; Fleischhacker WW
    J Clin Psychopharmacol; 1994 Aug; 14(4):241-6. PubMed ID: 7962679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study.
    Anghelescu IG; Kohnen R; Szegedi A; Klement S; Kieser M
    Pharmacopsychiatry; 2006 Nov; 39(6):213-9. PubMed ID: 17124643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of mania in depression by paroxetine.
    Morishita S; Arita S
    Hum Psychopharmacol; 2003 Oct; 18(7):565-8. PubMed ID: 14533140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
    Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
    Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, placebo-controlled study of paroxetine in depressed outpatients.
    Kiev A
    J Clin Psychiatry; 1992 Feb; 53 Suppl():27-9. PubMed ID: 1531818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paroxetine in depressed adolescents with intellectual disability: an open label study.
    Masi G; Marcheschi M; Pfanner P
    J Intellect Disabil Res; 1997 Jun; 41 ( Pt 3)():268-72. PubMed ID: 9219077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nefazodone in the treatment of severe, melancholic, and recurrent depression.
    Marcus RN; Mendels J
    J Clin Psychiatry; 1996; 57 Suppl 2():19-23. PubMed ID: 8626359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia.
    Mendels J; Kiev A; Fabre LF
    Depress Anxiety; 1999; 9(2):54-60. PubMed ID: 10207659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients.
    Fabre LF
    J Clin Psychiatry; 1992 Feb; 53 Suppl():40-3. PubMed ID: 1531823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time course of response to paroxetine: influence of plasma level.
    Gex-Fabry M; Gervasoni N; Eap CB; Aubry JM; Bondolfi G; Bertschy G
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 May; 31(4):892-900. PubMed ID: 17395353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superiority of escitalopram to paroxetine in the treatment of depression.
    Kasper S; Baldwin DS; Larsson Lönn S; Boulenger JP
    Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A placebo-controlled trial of paroxetine in the treatment of major depression.
    Smith WT; Glaudin V
    J Clin Psychiatry; 1992 Feb; 53 Suppl():36-9. PubMed ID: 1531822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melancholic/endogenous depression and response to somatic treatment and placebo.
    Peselow ED; Sanfilipo MP; Difiglia C; Fieve RR
    Am J Psychiatry; 1992 Oct; 149(10):1324-34. PubMed ID: 1388334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind comparison of paroxetine, imipramine, and placebo in major depression.
    Shrivastava RK; Shrivastava SH; Overweg N; Blumhardt CL
    J Clin Psychiatry; 1992 Feb; 53 Suppl():48-51. PubMed ID: 1531825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.